Full-Time

Senior Software Engineer

Navigation

Deadline 8/7/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$92k - $148.3k/yr

+ Long-Term Incentive Program + 401(k) match

Boston, MA, USA + 1 more

More locations: Columbia City, IN, USA

Hybrid

Hybrid role; some in-office days required.

Category
Software Engineering (1)
Required Skills
Microsoft Azure
Agile
Software Testing
Data Structures & Algorithms
Threat modeling
SQL
RDBMS
Docker
.NET
C#
SCRUM
REST APIs

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Computer Science, Computer/Software Engineering, Electrical Engineering, or related field. Master’s degree is a plus.
  • 5+ years of relevant industry experience
  • Strong proficiency in full-stack C#/.NET development, object oriented design, and core CS fundamentals (data structures, algorithms) including at least one front-end technology.
  • Demonstrated, hands-on, experience in developing and supporting a full-stack application system with customer facing front-end (GUI) that integrates with on-device and cloud backend systems.
  • Experience with Windows application development using Windows Presentation Foundation (WPF).
  • Excellent ability to author technical documentation for software applications.
  • Proficiency across the full Software Development Life Cycle in a regulated environment: requirements, design, implementation, testing, traceability, release, and maintenance.
  • Strong debugging and profiling skills on Windows; experience with CI/CD and automated testing.
  • Excellent communication, collaboration, and influence skills; ability to be a key participant in architecture and design reviews.
Responsibilities
  • Build production grade on device clinical applications and services in C#/.NET for Windows and iOS targets, integrating with local and cloud services.
  • Experience with relational databases and embedded databases such as SQLite, including schema design, data modeling, and data normalization. Strong proficiency in writing, optimizing, and debugging SQL queries.
  • Develop concurrent, multi threaded components and services using REST APIs and databases, with an architecture that supports evolution and versioning.
  • Use secure coding principles to ensure cybersecurity and patient safety with appropriate technologies and cybersecurity processes. Examples: X.509 device identity, mutual TLS, certificate rotation, secure storage (e.g., integration with Key Vault), threat modeling, and least privilege access.
  • Build cloud connected backends and integrations in Azure or similar cloud environments (Functions, App Service, containers where appropriate) to support telemetry ingestion, command routing, and fleet operations.
  • Drive software quality through unit/integration/system tests (including hardware in the loop), profiling, observability (structured logging, metrics, traces), and CI/CD integration.
  • Contribute to regulatory documentation, traceability, and V&V aligned with IEC 62304, ISO 14971, and related guidance; support submissions (e.g., FDA 510(k)) as needed.
  • Collaborate in Agile/Scrum workflows, mentor junior engineers, and lead design/code reviews to sustain long term maintainability.
Desired Qualifications
  • Experience with AI-driven development.
  • Experience with API development and integration with cloud services.
  • Experience in developing regulated medical device software (SaMD) under standards like IEC 62304, FDA cybersecurity guidance.
  • Experience with requirements, design documentation in tools like Polarion, JAMA, etc.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • J&J's stock surged 47.1% over the past year, outperforming the healthcare sector.
  • FDA approved J&J's Dual Energy cardiac ablation platform for electrophysiology in 2026.
  • J&J's 2026 revenue will exceed $100 billion for the first time in history.

What critics are saying

  • 58,206 pending talc ovarian cancer lawsuits risk multi-billion payouts within 12–24 months.
  • Eli Lilly's obesity drugs dominate 56% of its revenue, eroding J&J's pharma growth.
  • Abiomed's Impella trial failure forces J&J's cardiovascular unit to contract by 10–15%.

What makes Johnson & Johnson unique

  • J&J uniquely spans pharmaceuticals, MedTech, and consumer health across 140 years.
  • Its Dual Energy THERMOCOOL platform delivers both radiofrequency and pulsed field energy.
  • J&J raised 2026 revenue guidance to $100.8–$101.4 billion after Q2 beat.
  • J&J's oncology portfolio gained multiple FDA approvals in early 2026.
  • MedTech growth is fueled by Shockwave (2024) and Abiomed (2022) acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.